We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+29.44%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$215M
AUM Growth
+$17.5M
Cap. Flow
-$18.3M
Cap. Flow %
-8.51%
Top 10 Hldgs %
52.76%
Holding
47
New
10
Increased
10
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
AMAG
AMAG Pharmaceuticals
AMAG
+$9.06M
2
MDXG icon
MiMedx Group
MDXG
+$5.52M
3
ADMS
Adamas Pharmaceuticals
ADMS
+$4.37M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$3.58M
5
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$3.43M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$10.4M
2
CMRX
Chimerix, Inc.
CMRX
+$9.53M
3
TVTX icon
Travere Therapeutics
TVTX
+$6.4M
4
ARAV
Aravive, Inc. Common Stock
ARAV
+$5.28M
5
GNMK
GenMark Diagnostics, Inc
GNMK
+$4.56M

Sector Composition

Rank Sector Weight
1 Healthcare 97.86%
2 Miscellaneous 2.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMRX
1
DELISTED
Chimerix, Inc.
CMRX
$21.3M 9.89%
565,000
-240,000
-30% -$9.53M
CEMP
2
DELISTED
Cempra, Inc.
CEMP
$17.2M 7.96%
500,000
-4,800
-1% -$144K
ARIA
3
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$12.4M 5.74%
1,500,000
-25,000
-2% -$185K
TVTX icon
4
Travere Therapeutics
TVTX
$6.36B
$12M 5.56%
500,000
-420,000
-46% -$6.4M
CLVS
5
DELISTED
Clovis Oncology, Inc.
CLVS
$10.4M 4.82%
140,000
– –
AMAG
6
DELISTED
AMAG Pharmaceuticals
AMAG
$10.4M 4.82%
+190,000
New +$9.06M
AGIO icon
7
Agios Pharmaceuticals
AGIO
$2.05B
$8.49M 3.94%
90,000
-23,500
-21% -$2.63M
CDXS icon
8
Codexis
CDXS
$182M
$7.86M 3.65%
1,724,000
– –
GERN icon
9
Geron
GERN
$983M
$6.88M 3.19%
1,825,000
– –
GNMX
10
DELISTED
Aevi Genomic Medicine Inc
GNMX
$6.85M 3.18%
850,000
– –
RARE icon
11
Ultragenyx Pharmaceutical
RARE
$2.59B
$6.83M 3.17%
110,000
+3,800
+4% +$211K
SUPN icon
12
Supernus Pharmaceuticals
SUPN
$2.57B
$6.47M 3%
535,000
+185,000
+53% +$1.75M
TTPH
13
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$6.41M 2.98%
8,750
-735
-8% -$552K
INSY
14
DELISTED
Insys Therapeutics, Inc.
INSY
$6.39M 2.97%
220,000
-25,000
-10% -$661K
MDXG icon
15
MiMedx Group
MDXG
$657M
$6.14M 2.85%
+590,000
New +$5.52M
KYNB
16
Kyntra Bio
KYNB
$32.4M
$6M 2.79%
7,654
– –
NBIX icon
17
Neurocrine Biosciences
NBIX
$15.8B
$5.76M 2.67%
145,000
+100,000
+222% +$3.58M
HROW icon
18
Harrow
HROW
$1.44B
$5.49M 2.55%
687,100
+127,100
+23% +$972K
AVDL
19
DELISTED
Avadel Pharmaceuticals
AVDL
$5.39M 2.5%
300,000
+95,000
+46% +$1.49M
TRIL
20
DELISTED
Trillium Therapeutics Inc.
TRIL
$5.26M 2.44%
260,000
-73,333
-22% -$1.08M
ISEE
21
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$4.89M 2.27%
105,000
+5,000
+5% +$260K
ADMS
22
DELISTED
Adamas Pharmaceuticals
ADMS
$4.46M 2.07%
+255,000
New +$4.37M
KITE
23
DELISTED
Kite Pharma, Inc.
KITE
$4.38M 2.04%
76,000
– –
AMRN
24
Amarin Corp
AMRN
$297M
$4.1M 1.91%
+87,700
New +$2.68M
AXGN icon
25
Axogen
AXGN
$2.78B
$3.45M 1.6%
+985,900
New +$3.39M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2015 Portfolio in Review

As of Q1 2015, Opaleye Management held 47 positions worth $215M, up 8.8% from $198M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Opaleye Management withdrew a net $18.3M in Q1 2015, closing 10 positions and reducing 9 holdings. Its most notable exit was PHARMACYCLICS INC, an estimated $10.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 92% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in AMAG Pharmaceuticals worth $10.4M.

  • Opaleye Management's largest Q1 2015 buy was AMAG Pharmaceuticals: 190,000 shares worth $10.4M.
  • Opaleye Management added most to Neurocrine Biosciences in Q1 2015, an estimated $3.58M increase.
  • Opaleye Management's biggest Q1 2015 reduction was Chimerix, Inc., cutting an estimated $9.53M.
  • Opaleye Management fully exited PHARMACYCLICS INC in Q1 2015, selling an estimated $10.4M.
  • Opaleye Management's ten largest holdings make up 53% of its $215M portfolio in Q1 2015.
  • Opaleye Management opened 10 new positions and closed 10 in Q1 2015.
  • Opaleye Management's portfolio value rose 8.8% quarter-over-quarter to $215M.

Based on Opaleye Management's 13F filing for Q1 2015, filed 15 May 2015.